182 related articles for article (PubMed ID: 10463317)
1. Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans.
Schuh KJ; Walsh SL; Stitzer ML
Psychopharmacology (Berl); 1999 Jul; 145(2):162-74. PubMed ID: 10463317
[TBL] [Abstract][Full Text] [Related]
2. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans.
Walsh SL; Sullivan JT; Preston KL; Garner JE; Bigelow GE
J Pharmacol Exp Ther; 1996 Nov; 279(2):524-38. PubMed ID: 8930154
[TBL] [Abstract][Full Text] [Related]
3. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
Bickel WK; Stitzer ML; Bigelow GE; Liebson IA; Jasinski DR; Johnson RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):47-53. PubMed ID: 2459370
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment.
Stoops WW; Lofwall MR; Nuzzo PA; Craig LB; Siegel AJ; Walsh SL
Psychopharmacology (Berl); 2012 Oct; 223(4):427-38. PubMed ID: 22623016
[TBL] [Abstract][Full Text] [Related]
5. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
Strain EC; Walsh SL; Bigelow GE
Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
[TBL] [Abstract][Full Text] [Related]
6. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.
Nasser AF; Greenwald MK; Vince B; Fudala PJ; Twumasi-Ankrah P; Liu Y; Jones JP; Heidbreder C
J Clin Psychopharmacol; 2016 Feb; 36(1):18-26. PubMed ID: 26650971
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
[TBL] [Abstract][Full Text] [Related]
8. Acute administration of buprenorphine in humans: partial agonist and blockade effects.
Walsh SL; Preston KL; Bigelow GE; Stitzer ML
J Pharmacol Exp Ther; 1995 Jul; 274(1):361-72. PubMed ID: 7542336
[TBL] [Abstract][Full Text] [Related]
9. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal.
Paronis CA; Bergman J
J Pharmacol Exp Ther; 2011 Feb; 336(2):488-95. PubMed ID: 21051498
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
[TBL] [Abstract][Full Text] [Related]
12. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade.
Walsh SL; Chausmer AE; Strain EC; Bigelow GE
Psychopharmacology (Berl); 2008 Jan; 196(1):143-55. PubMed ID: 17909753
[TBL] [Abstract][Full Text] [Related]
14. The effects of buprenorphine in buprenorphine-maintained volunteers.
Strain EC; Walsh SL; Preston KL; Liebson IA; Bigelow GE
Psychopharmacology (Berl); 1997 Feb; 129(4):329-38. PubMed ID: 9085402
[TBL] [Abstract][Full Text] [Related]
15. Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course.
Bigelow GE; Preston KL; Schmittner J; Dong Q; Gastfriend DR
Drug Alcohol Depend; 2012 Jun; 123(1-3):57-65. PubMed ID: 22079773
[TBL] [Abstract][Full Text] [Related]
16. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
[TBL] [Abstract][Full Text] [Related]
17. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.
Rothman RB; Gorelick DA; Heishman SJ; Eichmiller PR; Hill BH; Norbeck J; Liberto JG
J Subst Abuse Treat; 2000 Apr; 18(3):277-81. PubMed ID: 10742642
[TBL] [Abstract][Full Text] [Related]
18. Differentiating the Effect of an Opioid Agonist on Cardiac Repolarization From µ-Receptor-mediated, Indirect Effects on the QT Interval: A Randomized, 3-way Crossover Study in Healthy Subjects.
Darpo B; Zhou M; Bai SA; Ferber G; Xiang Q; Finn A
Clin Ther; 2016 Feb; 38(2):315-26. PubMed ID: 26749217
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices.
Greenwald M; Johanson CE; Bueller J; Chang Y; Moody DE; Kilbourn M; Koeppe R; Zubieta JK
Biol Psychiatry; 2007 Jan; 61(1):101-10. PubMed ID: 16950210
[TBL] [Abstract][Full Text] [Related]
20. Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers.
Preston KL; Bigelow GE
J Pharmacol Exp Ther; 1993 Feb; 264(2):813-23. PubMed ID: 7679737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
